LABOPHARM ANNOUNCES INTENTION TO DELIST FROM NASDAQ

LAVAL, QC, June 21, 2011 /CNW/ -- 
- Company's Shares Will Continue to Trade on Toronto Stock Exchange -


LAVAL, QC, June 21, 2011 /CNW/ - Labopharm Inc. (TSX: DDS) (NASDAQ:
 DDSS) announced today its intention to delist its common shares from
 The Nasdaq Global Market as of the close of business on June 30, 2011. 
 The Company's common shares will continue to be listed on the Toronto
 Stock Exchange. Following its delisting from Nasdaq, the Company
 intends to voluntarily terminate its public reporting obligations under
 the U.S. Securities Exchange Act as soon as possible.


"The cost savings resulting from the Nasdaq delisting and termination of
 reporting obligations with the SEC in the U.S. will further preserve
 capital as the Company moves forward with its strategic review
 process," said Mark A. D'Souza, President and Chief Executive Officer.


As previously announced on December 31, 2010 and April 1, 2011, the
 Company received notices from Nasdaq that it had failed to maintain a
 minimum bid price of $1.00 per share and failed to maintain a minimum
 Market Value of Listed Securities (MVLS) of $50,000,000. In light of
 its current financial condition, the Company does not anticipate that
 it will be able to meet such minimums or continue to meet other Nasdaq
 listing standards in the future.


About Labopharm Inc.
Labopharm is focused on realizing value from its commercialized products
 and creating additional value by leveraging its emerging technology
 platforms to develop increasingly differentiated products. For more
 information, visit www.labopharm.com.


This press release contains forward-looking statements within the
 meaning of applicable Canadian Securities legislation and U.S.
 Securities Law,  including statements related to the Company's Nasdaq
 delisting, which reflect the Company's current expectations regarding
 future events. These forward-looking statements involve risks and
 uncertainties, many of which are beyond the Company's control. Actual
 events could differ materially from those projected herein and depend
 on a number of risks and uncertainties. For additional disclosure
 regarding these and other risks faced by Labopharm Inc., see the
 disclosure contained in its public filings in the U.S. with the
 Securities and Exchange Commission (SEC) and in Canada with the
 Canadian Securities Administrators (CSA), available on the Investor
 Relations section of the Company's website at www.labopharm.com and on the SEC's website at www.sec.gov and on the CSA's website at www.sedar.com. Investors are cautioned not to place undue reliance on these
 forward-looking statements. Unless required by law, the Company
 undertakes no obligation to update or revise the information contained
 in this press release, whether as a result of new information, future
 events, or circumstances or otherwise. 


To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/June2011/21/c8145.html



table tr valign="top" td align="left" buAt The Equicom Group/u/bbr/ Lawrence Chamberlainbr/ Media and Investor Relationsbr/ Tel:  [phone] ext. 257br/ a cr="true" href="mailto:[e-mail]"[e-mail]/abr/ br/ French:br/ Joe Racanellibr/ Tel:  [phone]br/ a cr="true" href="mailto:[e-mail]"[e-mail]/a /td /tr /table 

Copyright